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CASE REPORT
Pityriasis rosea-like Drug Eruption Induced by Imatinib 
Mesylate (Gleevec
TM)
Ah Young Cho, M.D., Dae Hun Kim, M.D., Myung Im, M.D., Young Lee, M.D., 
Young Joon Seo, M.D., Jeung Hoon Lee, M.D.
Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea 
Imatinib mesylate (Gleevec
TM, STI571), a selective inhibitor 
of BCR-ABL, c-Kit, and platelet-derived factor receptor, has 
been used to treat chronic myelogenous leukemia (CML) and 
gastrointestinal stromal tumors. Although its use has been 
associated with various adverse cutaneous reactions, pity-
riasis rosea-like drug eruptions are rare. Here, we report a 
case of pityriasis rosea-like drug eruption that developed 
following the administration of imatinib mesylate to treat 
CML. (Ann Dermatol 23(S3) S360∼S363, 2011)
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INTRODUCTION
Imatinib mesylate (Gleevec
TM, STI571) functions as a com-
petitive inhibitor at the adenosine triphosphate binding 
site of the enzyme, preventing the tyrosine phospho-
rylation of proteins involved in BCR-ABL signal trans-
duction
1. It has been approved for the treatment of chro-
nic myeloid leukemia and gastrointestinal stromal tumor 
and has been found efficacious in other neoplastic disea-
ses. Although its use has been associated with various ad-
verse cutaneous reactions, pityriasis rosea-like drug erup-
tions are rare. Here, we describe a 74-year-old female 
patient who presented with pityriasis rosea-like drug 
eruption that developed following the administration of 
imatinib mesylate to treat chronic myelogenous leukemia 
(CML). 
CASE REPORT 
A 74-year-old female patient was diagnosed with CML 
and treated with imatinib mesylate (Gleevec
TM) (400 
mg/day). After 1 month of treatment, she developed ede-
ma in her face and legs, which improved following 
treatment with diuretics. After 2 months of treatment, she 
developed non-pruritic, variably-sized, erythematous scaly 
patches along the cleavage lines of the trunk and extre-
mities (Fig. 1). Other than imatinib mesylate and diuretics, 
the patient was taking no other prescribed medicines. 
Laboratory findings revealed that she was suffering from 
pancytopenia, and a serological test for syphilis was 
negative. Histological analyses of the biopsy from the 
trunk revealed perivascular inflammatory infiltration by 
lymphocytes, a small number of eosinophils, and extra-
vasation of red blood cells into the superficial dermis. The 
epidermis was characterized by parakeratosis, acanthosis, 
spongiosis, lymphocyte exocytosis, scattered necrotic ke-
ratinocytes, and vacuolar alteration of keratinocytes in the 
basal layer of the epidermis (Fig. 2A, B). The intrae-
pidermal lymphocytes were primarily CD8＋ T cells, and 
the dermal perivascular and interstitial lymphocytes were 
primarily CD4＋  T cells (Fig. 2C, D). 
Discontinuation of imatinib mesylate therapy and the 
simultaneous initiation of systemic antihistamine and 
topical corticosteroid therapy brought about complete Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec
TM)
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Fig. 2. (A, B) Acanthosis, parake-
ratosis, spongiosis, lymphocyte exo-
cytosis, and the presence of necrotic 
keratinocytes in the epidermis. Va-
cuolar alterations at the dermo-epi-
dermal junction are evident. Infil-
tration by lymphocytes and a smal-
ler number of eosinophils, and ex-
travasation of red blood cells are 
observed in the superficial dermis 
(H&E; ×40, ×100). (C, D) The in-
traepidermal lymphocytes are pri-
marily CD8＋ T cells; and the der-
mal perivascular and interstitial lym-
phocytes, primarily CD4＋ T cells (C:
CD4, D: CD8, ×100).
Fig. 1. (A∼D) Erythematous scaly patches are seen distributed along the cleavage lines of the trunk and extremities.
remission of the cutaneous lesions within 2 weeks. When 
imatinib mesylate therapy was recommenced (400 mg/ 
day), a cutaneous rash reappeared 7 days later. Imatinib 
mesylate was subsequently replaced with nilotinib, a 
second-generation BCR-ABL tyrosine kinase inhibitor. The 
patient has since suffered no recurrence of the skin rash. 
Based on the drug history, clinical presentation, histo-
pathological findings, and clinical course, our patient was 
diagnosed with pityriasis rosea-like drug eruption induced 
by imatinib mesylate.AY Cho, et al
S362 Ann Dermatol
DISCUSSION
Imatinib mesylate (Gleevec
TM, STI571), a selective in-
hibitor of BCR-ABL, c-kit and platelet-derived factor recep-
tor (PDGFR), has been used to treat CML and gas-
trointestinal stromal tumors. Adverse reactions induced by 
imatinib mesylate include hematologic responses and 
non-hematologic responses, including nausea, vomiting, 
diarrhea, myalgia, edema, and skin rash
1,2. The cutaneous 
adverse reactions commonly induced by imatinib me-
sylate (Gleevec
TM) may be non-specific such as exan-
thematous rash, pruritus, and edema, or may show erup-
tions with distinctive clinical characteristics, as in Stevens- 
Johnson syndrome
3, acute generalized exanthematous 
pustulosis
4,5, exfoliative dermatitis
6-8, psoriasiform drug 
eruption or exacerbation of psoriasis
9,10, pityriasis rosea- 
like eruption
11,12, and oral lichenoid reaction
13,14.
Although the shin area showed similar features to pso-
riasis, the general morphology of cutaneous lesion were 
thin, fine scaly patches, not thick, crusted plaques, which 
does not correlate with psoriasis. Histologic examination 
showed pityriasis rosea-like features, such as patchy 
parakeratosis, focal spongiosis with lymphocytic exo-
cytosis, superficial perivascular lymphocytic infiltrate with 
red cell extravasation rather than characteristic features of 
psoriasis, or psoriasiform drug eruptions, such as neu-
trophilc infiltration and confluent parakeratosis. In ad-
dition, clinically typical pityriasis rosea like drug eruption 
may be characterized by a more psoriasiform histology. 
Therefore, our patient was diagnosis with pityriasis rosea or 
pityriasis rosea-like drug eruption. At first glance, we could 
not differentiate between pityriasis rosea-like drug eruption 
and classic pityriasis rosea, which was not associated with 
imatinib mesylate. However, we concluded that the 
eruptions were likely caused by imatinib mesylate for 
several reasons. First, histopathological features were 
different form classic pityriasis rosea. The CD8＋ T cells 
infiltrating the epidermis and CD4＋  T cells infiltrating the 
dermis were consistent with an allergic drug reaction
15. In 
classic pityriasis rosea, the intraepidermal and dermal T 
cells are typically CD4＋. Second, there was a strong 
correlation between the time course of the reaction and 
the administration of imatinib mesylate, as the skin rash 
subsided following the discontinuation of treatment using 
this medication. Third, the re-administration of imatinib 
mesylate caused the skin reaction to flare up again, which 
provided further evidence linking the 2 events.
Pityriasis rosea-like drug eruptions induced by imatinib 
mesylate are very rare. Only 4 cases have been docu-
mented in 2 reports
11,12. Konstantopoulos et al.
11 des-
cribed a case of typical pityriasis rosea associated with 
imatinib mesylate, but the authors did not present images 
of the affected skin and did not perform a biopsy. 
Re-challenge with imatinib mesylate was not possible, so 
the diagnosis was tentative. Therefore, we consider the 
report of Brazzelli et al.
12 to be the first to confirm this 
diagnosis. All three 3 they presented showed clinical 
features of atypical pityriasis rosea and histopathological 
evidence of non-specific drug eruptions, suggesting a 
diagnosis of pityriasis rosea-like eruptions induced by 
imatinib mesylate. 
Although the pathophysiology of the adverse cutaneous 
reactions is unclear, the relationship between incidence 
and dosage suggests that these reactions may stem from 
the pharmacological effects of imatinib mesylate, rather 
than a hypersensitivity reaction
2,16. The imatinib mesylate 
target, c-Kit, is normally expressed in basal epidermal 
keratinocytes, melanocytes, tissue mast cells, breast epi-
thelial cells, and dermal sweat glands, among other 
cells
17. The pathophysiology of adverse skin reactions may 
be attributable to the inhibition of c-Kit and/or PDGFR 
tyrosine kinase activity in these skin cells
2. 
Management of mild to moderate skin eruptions induced 
by imatinib mesylate is usually achieved by discontinuing 
the drug treatment. In patients presenting with severe rash 
or peripheral eosinophilia, oral steroid treatment (e.g., 
prednisolone, 1 mg/kg) is often helpful
18. For cases in 
which the re-administration of imatinib mesylate is ne-
cessary to treat the primary disorder (e.g., leukemia), it 
may be possible to continue imatinib mesylate treatment 
with concomitant short-term steroid therapy (predni-
solone, 5 mg/day). Alternatively, starting with a low dose 
of (100 mg/day) and gradually increasing the dosage may 
be successful
19. On a case-by-case basis, careful mana-
gement can allow patients who develop mild to moderate 
skin rashes on imatinib mesylate to continue with the 
treatment. In our case, when imatinib mesylate was 
re-administered at a same dose, the cutaneous rash 
reappeared. As a consequence, imatinib mesylate was 
replaced with nilotinib, a second-generation BCR-ABL 
tyrosine kinase inhibitor. Our patient has since suffered no 
recurrence of the skin rash. 
Various adverse events linked to the administration of 
imatinib mesylate have been reported. Here, we pre-
sented a rare case of pityriasis rosea-like drug eruption 
that developed following the administration of imatinib 
mesylate to treat CML.
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